Isbn: 9781617374364 - biomarkers in breast cancer: molecular diagnostics for predicting and monitoring therapeutic effect (13 risultati)

Taschenbuch. Condizione: Neu. Biomarkers in Breast Cancer | Giampietro Gasparini (u. a.) | Taschenbuch | xii | Englisch | 2010 | Humana Press | EAN 9781617374364 | Verantwortliche Person für die EU: Humana Press in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu. …

Condizione: New. In English.

Condizione: New. Editor(s): Gasparini, Giampietro; Hayes, Daniel F. Series: Cancer Drug Discovery and Development. Num Pages: 342 pages, 22 black & white illustrations, biography. BIC Classification: MJCL. Category: (P) Professional & Vocational. Dimension: 229 x 152 x 18. Weight in Grams: 477. . 2010. 1st ed. Softcover of orig. ed. 2006. Paperback. . . . . …

Condizione: New. pp. 356.

Paperback. Condizione: Brand New. reprint edition. 360 pages. 9.02x5.98x0.81 inches. In Stock.

Condizione: New. Editor(s): Gasparini, Giampietro; Hayes, Daniel F. Series: Cancer Drug Discovery and Development. Num Pages: 342 pages, 22 black & white illustrations, biography. BIC Classification: MJCL. Category: (P) Professional & Vocational. Dimension: 229 x 152 x 18. Weight in Grams: 477. . 2010. 1st ed. Softcover of orig. ed. 2006. Paperback. . . . . Books ship from the US and Ireland. …

Paperback. Condizione: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

Condizione: new. Questo è un articolo print on demand.

Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers. It is now well recognized that individualized cancer treatment planning, based on tumor characteristics specific to an individual's cancer, makes it easier to select those most likely to benefit from toxic cancer therapies and to avoid treating those least likely to benefit. In Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect, expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers, as well as examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines to the validation of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers. Authoritative and cutting-edge, Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect offers laboratory investigators developing new tumor markers, clinical investigators testing them, and clinicians using them an up-to-date understanding of both the prognostic/predictive indicators and the novel molecular-targeted therapies suitable for individualizing breast cancer therapy. 342 pp. Englisch.…

Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the.…

Condizione: New. Print on Demand pp. 356 23:B&W 6 x 9 in or 229 x 152 mm Perfect Bound on White w/Gloss Lam.

Condizione: New. PRINT ON DEMAND pp. 356.

Taschenbuch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers. It is now well recognized that individualized cancer treatment planning, based on tumor characteristics specific to an individual's cancer, makes it easier to select those most likely to benefit from toxic cancer therapies and to avoid treating those least likely to benefit. In Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect, expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers, as well as examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines to the validation of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers. Authoritative and cutting-edge, Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect offers laboratory investigators developing new tumor markers, clinical investigators testing them, and clinicians using them an up-to-date understanding of both the prognostic/predictive indicators and the novel molecular-targeted therapies suitable for individualizing breast cancer therapy.…